FOXC1 gene deletion is associated with eye anomalies in ring chromosome 6
β Scribed by Zhang, Hui Z. ;Li, Peining ;Wang, Dongmei ;Huff, Shannon ;Nimmakayalu, Manjunath ;Qumsiyeh, Mazin ;Pober, Barbara R.
- Publisher
- John Wiley and Sons
- Year
- 2003
- Tongue
- English
- Weight
- 187 KB
- Volume
- 124A
- Category
- Article
- ISSN
- 0148-7299
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
We report a case of ring chromosome 6 presenting with growth and mental retardation, cerebral dysgenesis, eye malformations, mixed hearing loss, and abnormal physical features. Fluorescent in situ hybridization (FISH) and microsatellite genotyping demonstrated segmental deletions of less than 6 Mb on 6p and 1β2 Mb on 6q. The primary karyotype is designated as 46,XY,r(6)(p25q27).ish r(6)(p25.1q27)(D6S344β, FOXC1β, D6S1574+, D6S281β, D6S297+). Secondary structural and numerical variants of the ring 6 were observed in 16% of the cells analyzed. Intragenic genotyping revealed deletion of the paternal FOXC1 gene, haploinsufficiency of which has been reported to cause eye anterior chamber developmental defects. Accordingly, we propose that our patient's ophthalmologic abnormalities result from haploinsufficiency of the transcription factor FOXC1. We present clinical and cytogenetic summaries on 23 reported cases of ring 6 and categorize them into mild, moderate, and severely affected groups. Further phenotype comparisons between cases with ring 6 and cases with only 6p or 6q terminal deletions suggest that genes important for hearing, vision, and central nervous system development remain to be identified in chromosome 6 terminal regions. Molecular definition of the fusion points and tissue mosaicism studies are necessary to better understand the genotypeβphenotype correlation of ring 6. We recommend ophthalmology, audiology, cardiology, and central nervous system examinations be part of the routine evaluation for children with a ring chromosome 6. Β© 2003 WileyβLiss, Inc.
π SIMILAR VOLUMES
TABLE I. Colony-Forming Assay From CD34 + Bone Marrow Cells Serum a BFU-E/10 2 CD34 + cells Control 1 50.2 Β± 4.6 Control 2 48.5 Β± 14.1 Before chemotherapy 24.4 Β± 6.2 b After chemotherapy 50.5 Β± 6.5 Values are means Β± SD of triplicate cultures. a Control 1; normal AB serum, Control 2; serum from a pa